Assenagon Asset Management S.A. Arcus Biosciences, Inc. Transaction History

Assenagon Asset Management S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 18, 2024	SELL	$14.59 - $18.48 $8,039 - $10,182	-551 Reduced 1.39%	39,180 $596,000
Q1 2024 Apr 24, 2024	SELL	$14.83 - $20.18 $111,551 - $151,793	-7,522 Reduced 15.92%	39,731 $750,000
Q4 2023 Jan 17, 2024	BUY	$13.43 - $19.63 $634,607 - $927,576	47,253 New	47,253 $902,000
Q4 2022 Jan 12, 2023	BUY	$19.7 - $35.71 $2.28 Million - $4.13 Million	115,651 New	115,651 $2.39 Million
Q2 2021 Jul 15, 2021	SELL	$22.75 - $35.77 $256,574 - $403,414	-11,278 Closed	0 $0
Q1 2021 Apr 26, 2021	SELL	$26.16 - $41.39 $795,159 - $1.26 Million	-30,396 Reduced 72.94%	11,278 $317,000
Q4 2020 Feb 01, 2021	SELL	$17.0 - $32.36 $4.7 Million - $8.95 Million	-276,613 Reduced 86.91%	41,674 $1.08 Million
Q3 2020 Oct 07, 2020	BUY	$17.14 - $25.47 $2.95 Million - $4.38 Million	172,135 Added 117.78%	318,287 $5.46 Million
Q2 2020 Jul 21, 2020	BUY	$13.97 - $36.56 $2.04 Million - $5.34 Million	146,152 New	146,152 $3.62 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.